Home / Health / FDA Approves Groundbreaking Gene Therapy for Hearing Loss
FDA Approves Groundbreaking Gene Therapy for Hearing Loss
24 Apr
Summary
- A new gene therapy is approved to treat a rare hearing loss.
- This therapy replaces a faulty gene, restoring otoferlin protein production.
- The treatment significantly improved hearing in most children tested.
A significant medical advancement has been achieved with the U.S. approval of Otarmeni, a novel gene therapy designed to combat a rare form of hearing loss. This condition stems from a mutation in the OTOF gene, impacting approximately 50 infants born in the U.S. each year. The therapy works by introducing a correct copy of the OTOF gene, which instructs the body to produce the otoferlin protein. This protein is crucial for transmitting auditory signals from the ear to the brain.
Clinical trials demonstrated remarkable efficacy, with 16 out of 20 children experiencing improved hearing after receiving a single dose. Notably, five children developed the ability to detect whispers. This gene therapy offers a continuous solution, unlike cochlear implants which require batteries and may reduce sound fidelity. Side effects observed included middle ear infection, inflammation, nausea, vomiting, and dizziness.
The drugmaker has committed to providing the drug free of charge to U.S. patients. The administration of the therapy involves a procedure similar to cochlear implant surgery, requiring general anesthesia. While the drug's price for international markets is not yet established, gene therapies can cost millions. This development was highlighted by President Donald Trump as part of a drug pricing initiative.
